Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC for Rheumatoid Arthritis
NCT02643823Phase 1Unknown
- Sponsor
- Shenzhen Hornetcorn Biotechnology Co., Ltd.
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human umbilical cord mesenchymal stem cells in rheumatoid arthritis (RA) (2 arms), sponsored by Shenzhen Hornetcorn Biotechnology Co., Ltd. Primary endpoint: Severity of adverse events at 12 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02643823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643823.